宜宾做全切双眼皮要多少钱(宜宾双眼皮费用高不高) (今日更新中)

BEIJING, June 27 (Xinhuanet) -- A "lean gene" that helps people keep slim was found closely related to diabetes and heart disease, according to a study pulished in Nature Genetics journal on Sunday.The scientists from Britain’s Medical Research Council Epidemiology Unit conducted the study.After comparing the genetic codes of more than 75,000 people, a gene called IRS1 was spotted as the decisive factor to lower the fat level in human body.But in further study, IRS1 was found putting people to a 20 percent higher risk of developing heart disease and type-2 diabetes.The study warned that people who appear slim and fit might be also at risk.But scientists suggest that the study results did not change the general message for most people."While this study pointed to genes as one factor in determining the risk of developing these conditions, it was important to remember that lifestyle factors like diet, exercise, cutting out smoking and maintaining a healthy weight also play a vital role in reducing the risk," said Ruth Loos, who led the study.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.

BEIJING, June 3 (Xinhua) -- Google lacked evidence to support its accusations that Chinese hackers are behind the alleged cyber attacks on hundreds of its email accounts and the timing to make such accusations is evil-intentioned, Chinese experts said on Friday."Google's accusation is neither serious nor credible as it has not published any evidence that shows the hackers are from China," said Dai Yiqi, a cyber security expert with Tsinghua University.Eric Grosse, engineering director of Google's Security Team wrote on the company blog Wednesday that unidentified hacker attacks likely originated from the eastern Chinese city of Jinan, tried to collect user passwords of the Gmail accounts of hundreds of users, including senior U.S. government officials, Chinese "human rights activists" and journalists.A report released in 2009 by the United States-China Economic and Security Review Commission, an organization created by the U.S. Congress, claimed that Jinan is the home of a Chinese military reconnaissance office.An anonymous cyber security expert believes, despite Google not referring to the Chinese government in the latest attack claim, the company is targeting the Chinese government by listing the victims of the attacks as those whom only the Chinese government are interested in."Both their intentions and the timing of the accusation are dubious," Dai said.Google's accusation followed on the heel of the reported Pentagon's first formal cyber strategy. The Wall Street Journal reported Tuesday that the Pentagon concluded that computer sabotage coming from another country can count as an act of war and the United States may respond by using traditional military force.Li Shuisheng, a research fellow with a top military science academy of the People's Liberation Army, believes there are political motives behind Google's accusation.Google may well have attempted to instigate a new round of the cyber row between China and the United States, Li said.Wednesday's accusation by Google came more than a year after the company allegedly uncovered a cyber attack on its systems that it said it traced to China.In January, 2010, Google said it had been attacked by hackers supported by the Chinese government, and later announced to withdraw from Chinese mainland. The row ended up with Google redirecting Chinese mainland users to a site in Hong Kong.In such cyber attacks, it is easy to locate the IP address of hackers but hard to tell where the hackers actually are, said Dai."Hackers usually launch attacks by camouflaging their own IP addresses or controlling computers of others. Therefore, we can hardly tell the location of the hacker unless we have sufficient evidence," he said.China is one of the leading targets of cyber attacks. It has the world's largest number of computers infected with bot, a type of malware which allows a cyber attacker to gain control over the affected computer.About 13 percent of the world's computers infected with bot are in China."Without cooperation between governments, absolute security cannot be guaranteed in cyber community," said Li , adding only cooperation can ensure safe information exchange.

KATHMANDU, Aug. 7 (Xinhua) -- Ban on smoking in public places will be enforced from Sunday with the Tobacco Control and Regulatory Act-2010 coming into effect.Those smoking in public places will be fined and civil servants will be liable to departmental action.Government offices, corporations, educational institutions, libraries, airports, public vehicles, orphanages, childcare centres, cinema halls, homes for the elderly, cultural centres, children's gardens, hotels, restaurants, resorts, girls' and boys' hostels, department stores, religious sites and industries have been designated no-smoking zones.Health Secretary Sudha Sharma said mass awareness campaign highlighting punishment will be carried out. She also said an inter-ministerial coordinating committee has been formed to enforce the law to ensure people's right to health. Pasting no- smoking notices at every public place will be mandatory.According to The Himalayan Times daily, the ban covers sale of tobacco products and single sticks within a 100-meter radius of educational and health institutions, children's homes, child care centers and home for elders.Anyone selling tobacco products to persons under the age of 18 years and pregnant women will be fined.The Act also prohibits advertising and sponsoring programs in the name of tobacco-related products through media. Offenders will be fined.The government's mass awareness campaign will cover the entire country to ensure effective implementation of the Act.

SYDNEY, Sept. 5 (Xinhua) -- Australian scientists believe " brown fat," a wondrous tissue that burns energy to generate heat, could help people fight obesity, local media reported on Monday.A research team from Sydney's Garvan Institute of Medical Research (GIMR) has worked out how to grow brown fat from stem cells biopsied from adults, raising hopes that one day brown fat could be transplanted in obese people to speed up calories they burn, the Australian Associated Press (AAP) reported.Garvan endocrinologist Paul Lee, who led the research, is optimistic about targeting brown fat as an obesity intervention, commenting "it's a highly metabolically active form of fat, and very exciting that we may be able to stimulate its growth in people."People are born with supplies of brown fat around their neckline to keep them warm as infants, according to scientists at GIMR.Scientists now know that brown fat is present in most, if not all, adults mainly just behind the collarbone.Studies have found that adults with brown fat are slimmer than those without."Although this is early work, it is a proof of concept study showing that the growth of brown fat cells is possible, using precursor cells taken from adult humans, under appropriate stimulation," Lee said."Regardless of whether or not someone has lots of or little brown fat, the precursor cells are universally present. Under the appropriate growth factor and hormonal stimulation, the cells all grow and differentiate into mature brown fat cells."However, Lee warned more work was needed.Lee said even if brown fat was transplanted into obese people or drugs developed to stimulate the growth of brown fat, exercise and a healthy diet would still be crucial to aiding weight loss."So I don't think this is a solution to obesity because there are so many other factors (involved in obesity)," he said."Despite how efficient brown fat is at burning energy, we would only need a few doughnuts to diminish or negate its benefits."Lee said it would be years before tests could be carried out on brown fat transplants.In the meantime, he is expanding his study to test different ways to grow brown fat.His study, to be printed in the October issue of Endocrinology, has been published in the online edition of the journal.

来源：资阳报